Sarepta's EXONDYS 51 books $16.3M in Q1 driving 241% increase in earnings; shares slip 3% after hours as investors sell on news

|About: Sarepta Therapeutics, ... (SRPT)|By:, SA News Editor

Sarepta Therapeutics (NASDAQ:SRPT) Q1 results ($M): EXONDYS 51 sales: 16.3 (consensus: 13.9).

Net Income: 84.1 (+240.6%): Non-GAAP Net Income: (33.0) (+37.1%); EPS: 1.50 (+214.5%); Non-GAAP EPS: (0.60) (+47.8%).

2017 Guidance: Revenue: greater than $95M from at least $80M.

Shares are down 3% after hours on robust volume